Coherus Oncology (CHRS) Payables: 2013-2025
Historic Payables for Coherus Oncology (CHRS) over the last 12 years, with Sep 2025 value amounting to $24.9 million.
- Coherus Oncology's Payables rose 13.70% to $24.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $131.9 million, marking a year-over-year decrease of 23.41%. This contributed to the annual value of $28.5 million for FY2024, which is 19.20% down from last year.
- Latest data reveals that Coherus Oncology reported Payables of $24.9 million as of Q3 2025, which was down 33.83% from $37.6 million recorded in Q2 2025.
- Coherus Oncology's 5-year Payables high stood at $126.7 million for Q3 2021, and its period low was $9.9 million during Q3 2022.
- In the last 3 years, Coherus Oncology's Payables had a median value of $35.2 million in 2023 and averaged $35.8 million.
- Its Payables has fluctuated over the past 5 years, first spiked by 956.59% in 2021, then tumbled by 92.17% in 2022.
- Over the past 5 years, Coherus Oncology's Payables (Quarterly) stood at $16.2 million in 2021, then decreased by 28.67% to $11.5 million in 2022, then surged by 205.56% to $35.2 million in 2023, then dropped by 19.20% to $28.5 million in 2024, then rose by 13.70% to $24.9 million in 2025.
- Its Payables was $24.9 million in Q3 2025, compared to $37.6 million in Q2 2025 and $40.9 million in Q1 2025.